ReviewAdvances in hematology2016
Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance.
Review in Advances in hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Trial
- Recrudescence of a FLT3 wild-type CMML clone after allogeneic stem cell transplant for FLT3-ITD acute myeloid leukemia.The oncologist · 2026Article
- A Lesson of Immunosuppression in Renal Transplant: Retreat or Hold?The Yale journal of biology and medicine · 2023Observational
- Kidney Transplant Outcomes of Patients With Multiple Myeloma.Kidney international reports · 2022Article
- Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis.Experimental hematology & oncology · 2022Article
- Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans.Frontiers in immunology · 2022Review
- The intragraft vascularized bone marrow component plays a critical role in tolerance induction after reconstructive transplantation.Cellular & molecular immunology · 2021Article
- Bone Fragment Co-transplantation Alongside Bone Marrow Aspirate Infusion Protects Kidney Transplant Recipients.Frontiers in immunology · 2021Article
- Medawar's Paradox and Immune Mechanisms of Fetomaternal Tolerance.OBM transplantation · 2020Article
- Tandem Orthotopic Living Donor Liver Transplantation Followed by Same Donor Haploidentical Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency.Transplantation · 2019Article
- Post-transplantation cyclophosphamide for chimerism-based tolerance.Bone marrow transplantation · 2019Review
- Summary of the Third International Workshop on Clinical Tolerance.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Article
- Cyclophosphamide and fludarabine monophosphate dose optimization for the non-myeloablative condition in non-human primates to induce transient mixed chimerism via bone marrow transplantation.American journal of translational research · 2019Article
- Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach.Human immunology · 2018Review
- Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.Blood advances · 2018Review
- Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.Journal of the American Society of Nephrology : JASN · 2018Review
- Split Tolerance in a Murine Model of Heterotopic En Bloc Chest Wall Transplantation.Plastic and reconstructive surgery. Global open · 2017Article
- Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The induction of specific tolerance, in order to avoid the detrimental effects of lifelong systemic immunosuppressive therapy after organ transplantation, has been considered the "Holy Grail" of transplantation. Experimentally, tolerance has been achieved through clonal deletion, through costimulatory blockade, through the induction or infusion of regulatory T-cells, and through the establishment of hematopoietic chimerism following donor bone marrow transplantation. The focus of this review is how tolerance has been achieved following combined bone marrow and kidney transplantation. Preclinical models of combined bone marrow and kidney transplantation have shown that tolerance can be achieved through either transient or sustained hematopoietic chimerism. Combined transplants for patients with multiple myeloma have shown that organ tolerance and prolonged disease remissions can be accomplished with such an approach. Similarly, multiple clinical strategies for achieving tolerance in patients without an underlying malignancy have been described, in the context of either transient or durable mixed chimerism or sustained full donor hematopoiesis. To expand the chimerism approach to deceased donor transplants, a delayed tolerance approach, which will involve organ transplantation with conventional immunosuppression followed months later by bone marrow transplantation, has been successful in a primate model. As combined bone marrow and organ transplantation become safer and increasingly successful, the achievement of specific tolerance may become more widely applicable.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.